Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell

Yun Kyoung Kang1, Rachel Schiff, Lan Ko

  • 1Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.

Cancer Research
|October 3, 2008
PubMed

Insights

Coactivator activator (CoAA) acts as a tumor suppressor in kidney cancer by inhibiting cell growth and down-regulating the c-myc oncogene. A related isoform, CoAM, counterbalances this effect.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Epigenetics

Background:

  • Coactivator activator (CoAA) is known to regulate transcription and RNA splicing.
  • Its role in cancer, particularly kidney cancer, is not well understood.

Purpose of the Study:

  • To investigate the function of CoAA as a coregulator in human kidney cells.
  • To determine CoAA's role in renal cell carcinoma (RCC).

Main Methods:

  • Assessed CoAA's effect on cell cycle progression (G1-S transition) and anchorage-independent growth.
  • Analyzed the regulation of c-myc, ccnd1, skp2, and p27/Kip1 protein levels.
  • Investigated CoAA's mechanism of c-myc repression involving HDAC3, histone acetylation, and RNA polymerase II recruitment.
  • Examined the function of the CoAA splicing isoform, coactivator modulator (CoAM).
  • Compared CoAA protein expression in normal kidney tissue versus RCC.

Main Results:

  • CoAA inhibits G1-S transition, anchorage-independent growth, and xenograft tumor formation.
  • CoAA down-regulates c-myc, ccnd1, and skp2, leading to p27/Kip1 accumulation.
  • CoAA represses c-myc by recruiting HDAC3, reducing histone H3 acetylation and RNA polymerase II at the c-myc promoter.
  • The CoAM isoform antagonizes CoAA's inhibitory effects.
  • CoAA protein expression is significantly decreased in human RCC compared to normal kidney tissue.

Conclusions:

  • CoAA functions as a dual-role coregulator, inhibiting cell cycle progression and tumor growth.
  • CoAA acts as a tumor suppressor in renal carcinoma by repressing the proto-oncogene c-myc.
  • CoAM serves as a counterbalancing splice isoform.
  • CoAA represents a novel nuclear receptor coregulator involved in kidney cancer suppression, highlighting potential new roles for coregulators in RCC biology.

Related Concept Videos

Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Eukaryotic Transcription Activators02:42

Eukaryotic Transcription Activators

Transcription activators are proteins that promote the transcription of genes from DNA to RNA. In most cases, these proteins contain two separate domains ‒ a domain that binds to DNA and a domain for activating transcription; however, in some cases, a single domain is responsible for both binding and activation of transcription, as seen in the glucocorticoid receptor and MyoD.
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These domains are...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
RNA Polymerase II Accessory Proteins02:36

RNA Polymerase II Accessory Proteins

Proteins that regulate transcription can do so either via direct contact with RNA Polymerase or through indirect interactions facilitated by adaptors, mediators, histone-modifying proteins, and nucleosome remodelers. Direct interactions to activate transcription is seen in bacteria as well as in some eukaryotic genes. In these cases, upstream activation sequences are adjacent to the promoters, and the activator proteins interact directly with the transcriptional machinery. For example, in...